Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

MS trials. The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events. Eligible patients in this trial are now receiving dirucotide on an un-blinded basis to the end of their 27th month in the trial.

Licensing and Development Agreement with Lilly

On December 17, 2007, BioMS entered into a licensing and development agreement (the "Agreement") granting Lilly exclusive worldwide rights to dirucotide. The transaction closed on January 25, 2008 and BioMS received an upfront payment of US $87 million. In September 2008, BioMS received a development milestone payment of US $10 million as a result of the positive interim analysis from the DSMB for MASESTRO-01. BioMS has the potential to receive future development and sales milestones up to US $400 million and escalating royalties on sales if dirucotide is commercialized.

Not later than sixty (60) days following receipt of the final written report of the results of the MAESTRO-01 trial, Lilly shall notify BioMS in writing whether Lilly will terminate the Agreement or alternatively Lilly shall bear 100% of any and all continuing development costs incurred by Lilly or BioMS for dirucotide.

HYC750 and BioCyDex

On May 9, 2008, BioMS entered into a Royalty and Assignment Agreement with Orcrist Bio. Inc. for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic uses and is being developed as a treatment for the side effects of chemotherapy. BioMS held an exclusive worldwide license to HYC750 from the University of Alberta. As a result of the Royalty and Assignment Agreement, BioMS terminated its license with the University of Alberta and the University entered into
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Yves Lionel Assant is,the new Chairman of Gerresheimer,s ... was already a member of the Supervisory Board. ... position for personal reasons. He,remains a member of ... & life science supply and services,company with market ...
... Stephen Simes, chief executive,officer of BioSante Pharmaceuticals, ... be featured in an exclusive interview with, http://www.wallst.net ... EDT. The interview,will be posted on http://www.wallst.net ... The interview will cover topics including BioSante,s ...
... Calif., Sept. 24 Today, the rights ... utilize PARI,s,eFlow electronic nebulizer for aerosol delivery ... of Corus Pharma in,August 2006, this is ... eFlow is featured prominently in the development ...
Cached Biology Technology:WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals 2Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca 2
(Date:10/14/2014)... Mount Sinai-led research team has discovered a new kind of ... a cell that lines liver blood vessels, according to a ... . The existence of such a cell type contradicts current ... embryo, and may hold clues to origins of, and future ... from a single cell into a complex being made up ...
(Date:10/14/2014)... CA – October 14, 2014 – Scientists from The ... from the National Institutes of Health (NIH) to lead ... virus-induced hemorrhagic fever disease in Africa. The study aims ... why some patients die, while others survive the inflection. ... understand the basic mechanism of how Lassa fever virus ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
Breaking Biology News(10 mins):Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Department of Energy,s Savannah River National Laboratory (SRNL) ... University to decrease mold growth in flooded homes ... by the Department of Homeland Security (DHS) through ... University asked SRNL and Tuskegee University to join ...
... JOLLA, Calif., July 14, 2010 Put simply, a tumor ... the cell cycle the cell,s process of duplicating itself ... of proteins tells other proteins what to do and when ... regulation fail, cell growth can get out of hand. A ...
... -- The 52nd meeting of the American Association ... - 22, 2010 in Philadelphia, PA. AAPM ... broadly-based scientific and professional discipline encompassing physics principles ... includes medical physicists who specialize in research that ...
Cached Biology News:SRNL works to decrease hazards from mold in water damaged homes 2New role for the JNK protein 2Nanotech medicine, tumor tracking, new technologies and more 2Nanotech medicine, tumor tracking, new technologies and more 3Nanotech medicine, tumor tracking, new technologies and more 4Nanotech medicine, tumor tracking, new technologies and more 5Nanotech medicine, tumor tracking, new technologies and more 6Nanotech medicine, tumor tracking, new technologies and more 7Nanotech medicine, tumor tracking, new technologies and more 8Nanotech medicine, tumor tracking, new technologies and more 9Nanotech medicine, tumor tracking, new technologies and more 10Nanotech medicine, tumor tracking, new technologies and more 11Nanotech medicine, tumor tracking, new technologies and more 12Nanotech medicine, tumor tracking, new technologies and more 13Nanotech medicine, tumor tracking, new technologies and more 14Nanotech medicine, tumor tracking, new technologies and more 15Nanotech medicine, tumor tracking, new technologies and more 16Nanotech medicine, tumor tracking, new technologies and more 17